Beta-Caryophyllene
CAS 87-44-5
Beta-Caryophyllene (CAS 87-44-5) is a Phase 1 pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 41397.5 nM | 4 | - |
| - | MIC | 521.5625 ug.mL-1 | 4 | - |
| - | EC50 | 5740 nM | 2 | - |
| - | Ki | 150 nM | 1 | - |
| - | Potency | 39810.7 nM | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BETA-CARYOPHYLLENE | 134695 | SU | MTHSPL |
| CARYOPHYLLENE | 1368148 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Beta-Caryophyllene used for in pharmaceutical contexts?
Beta-Caryophyllene (CAS 87-44-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Beta-Caryophyllene?
No adverse-event association or SIDER side-effect rows are rendered for Beta-Caryophyllene in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Beta-Caryophyllene also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Beta-Caryophyllene with EU status "restricted".
What clinical phase is Beta-Caryophyllene in?
Beta-Caryophyllene is rendered with ChEMBL max phase 1.